IL195037A - Linker proteins that link to hepatocyte growth, methods for their production and use - Google Patents

Linker proteins that link to hepatocyte growth, methods for their production and use

Info

Publication number
IL195037A
IL195037A IL195037A IL19503708A IL195037A IL 195037 A IL195037 A IL 195037A IL 195037 A IL195037 A IL 195037A IL 19503708 A IL19503708 A IL 19503708A IL 195037 A IL195037 A IL 195037A
Authority
IL
Israel
Prior art keywords
methods
growth factor
binding proteins
hepatocyte growth
producing same
Prior art date
Application number
IL195037A
Other languages
English (en)
Hebrew (he)
Other versions
IL195037A0 (en
Original Assignee
Xoma Technology Ltd
Aveo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Technology Ltd, Aveo Pharmaceuticals Inc filed Critical Xoma Technology Ltd
Publication of IL195037A0 publication Critical patent/IL195037A0/en
Publication of IL195037A publication Critical patent/IL195037A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
IL195037A 2006-06-02 2008-11-02 Linker proteins that link to hepatocyte growth, methods for their production and use IL195037A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81071406P 2006-06-02 2006-06-02
US86050906P 2006-11-21 2006-11-21
PCT/US2007/012939 WO2007143090A2 (en) 2006-06-02 2007-06-01 Hepatocyte growth factor (hgf) binding proteins

Publications (2)

Publication Number Publication Date
IL195037A0 IL195037A0 (en) 2011-08-01
IL195037A true IL195037A (en) 2015-08-31

Family

ID=38802077

Family Applications (2)

Application Number Title Priority Date Filing Date
IL195037A IL195037A (en) 2006-06-02 2008-11-02 Linker proteins that link to hepatocyte growth, methods for their production and use
IL219654A IL219654A0 (en) 2006-06-02 2012-05-08 Binding proteins that bind hepatocyte growth factor and methods of producing the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL219654A IL219654A0 (en) 2006-06-02 2012-05-08 Binding proteins that bind hepatocyte growth factor and methods of producing the same

Country Status (20)

Country Link
US (5) US7649083B2 (https=)
EP (2) EP2027156B9 (https=)
JP (3) JP4686634B2 (https=)
KR (1) KR101196060B1 (https=)
AR (1) AR061171A1 (https=)
AT (1) ATE495195T1 (https=)
AU (1) AU2007254942B2 (https=)
BR (1) BRPI0712222B1 (https=)
CA (1) CA2654025C (https=)
CY (1) CY1111714T1 (https=)
DE (1) DE602007011923D1 (https=)
DK (1) DK2027156T3 (https=)
IL (2) IL195037A (https=)
MX (1) MX2008014829A (https=)
NO (1) NO345476B1 (https=)
NZ (1) NZ573818A (https=)
PL (1) PL2027156T3 (https=)
PT (1) PT2027156E (https=)
SG (1) SG158112A1 (https=)
WO (1) WO2007143090A2 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI476206B (zh) 2003-07-18 2015-03-11 Amgen Inc 對肝細胞生長因子具專一性之結合劑
AU2007254853B2 (en) * 2006-06-02 2011-11-17 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
US7649083B2 (en) * 2006-06-02 2010-01-19 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding antibody
US20080233660A1 (en) * 2007-03-23 2008-09-25 Mu Bioteknik Ab Solid phase labeling method
EP2173379B2 (en) 2007-07-02 2023-07-05 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
BRPI0819598A2 (pt) 2007-11-30 2017-05-09 Kalobios Pharmaceuticals Inc anticorpos para o antígeno pcrv da pseudomonas aeruginosa
PT2271670E (pt) * 2008-03-14 2014-11-28 Allergan Inc Ensaio imunobaseado da atividade do serotipo a da toxina botulínica
KR101590495B1 (ko) 2008-05-29 2016-02-01 갤럭시 바이오테크, 엘엘씨 염기성 섬유모세포 성장 인자에 대한 모노클로날 항체
HUE035700T2 (en) 2008-11-07 2018-05-28 Galaxy Biotech Llc Monoclonal antibodies to Fibroblast Growth Factor receptor 2
WO2010119991A2 (en) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Novel method of treating cancer
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
MX2013002084A (es) 2010-08-31 2013-05-09 Genentech Inc Biomarcadores y metodos de tratamiento.
EP3604339B1 (en) 2011-01-14 2021-03-10 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
JP6185463B2 (ja) 2011-07-15 2017-08-23 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｒｓｐｏ結合剤およびその使用法
KR20140067052A (ko) 2011-09-09 2014-06-03 암젠 인코퍼레이티드 식도암 및 위암 환자들에서 항-간세포 성장 인자（“ｈｇｆ”） 항체들의 유효성을 예측하기 위한 ｃ―ｍｅｔ 단백질의 용도
SG11201400724SA (en) 2011-09-19 2014-04-28 Genentech Inc Combination treatments comprising c-met antagonists and b-raf antagonists
US9181333B2 (en) 2012-07-13 2015-11-10 Oncomed Pharmaceuticals, Inc. RSPO3 binding agents and uses thereof
JP2016509045A (ja) 2013-02-22 2016-03-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんを治療し、薬剤耐性を防止する方法
US9062104B2 (en) * 2013-03-14 2015-06-23 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
US9481725B2 (en) * 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
US9732150B2 (en) * 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
WO2014153166A2 (en) * 2013-03-14 2014-09-25 Alder Biopharmaceuticals, Inc. Therapeutic use of antibodies to hgf
RU2652880C2 (ru) * 2013-04-07 2018-05-03 Дженрикс (Шанхай) Байофармасертикал Ко., Лтд. Антитело против рецептора эпидермального фактора роста
WO2015031578A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Hgf assay
RU2016141385A (ru) 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
RU2016144405A (ru) 2014-05-23 2018-06-26 Дженентек, Инк. MiT БИОМАРКЕРЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
AU2015301538A1 (en) * 2014-08-15 2017-03-02 Oncomed Pharmaceuticals, Inc. RSPO1 binding agents and uses thereof
CA2961374A1 (en) 2014-09-16 2016-03-24 Oncomed Pharmaceuticals, Inc. Treatment of fibrotic diseases
WO2017070567A1 (en) * 2015-10-21 2017-04-27 The Research Foundation For The State University Of New York Klebsiella pneumoniae antibodies and methods to treat klebsiella pneumoniae infections
AU2020327537A1 (en) 2019-08-12 2022-03-03 Interna Technologies B.V. New treatments involving miRNA-193a
CN115461461A (zh) 2020-02-28 2022-12-09 因特尔纳技术有限公司 用于促进免疫原性细胞死亡的miRNA-193a
CA3191184A1 (en) * 2020-08-28 2022-03-03 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Signal peptide for reducing end heterogeneity of heterologous polypeptide
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US6498144B1 (en) 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5837676A (en) * 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
WO2001034650A1 (en) 1999-11-09 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services Hgf-sf monoclonal antibody combinations
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
TWI476206B (zh) * 2003-07-18 2015-03-11 Amgen Inc 對肝細胞生長因子具專一性之結合劑
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
CA2607699A1 (en) * 2005-06-02 2006-12-07 Galaxy Biotech, Llc Methods of treating brain tumors with antibodies
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
AU2007254853B2 (en) 2006-06-02 2011-11-17 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
US7649083B2 (en) 2006-06-02 2010-01-19 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding antibody
KR100829972B1 (ko) 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법
KR100881825B1 (ko) * 2007-07-27 2009-02-03 주식회사 하이닉스반도체 반도체 소자 및 그 제조 방법

Also Published As

Publication number Publication date
AU2007254942A1 (en) 2007-12-13
CA2654025C (en) 2016-08-02
BRPI0712222B1 (pt) 2021-10-13
US20100173362A1 (en) 2010-07-08
JP2009539347A (ja) 2009-11-19
DE602007011923D1 (de) 2011-02-24
IL195037A0 (en) 2011-08-01
PT2027156E (pt) 2011-04-18
HK1129395A1 (en) 2009-11-27
BRPI0712222A2 (pt) 2012-01-10
AR061171A1 (es) 2008-08-06
AU2007254942A2 (en) 2009-05-28
US20080108565A1 (en) 2008-05-08
DK2027156T3 (da) 2011-04-26
JP2011072318A (ja) 2011-04-14
IL219654A0 (en) 2012-06-28
ATE495195T1 (de) 2011-01-15
US7649083B2 (en) 2010-01-19
NO345476B1 (no) 2021-02-22
US8580930B2 (en) 2013-11-12
US20130203963A1 (en) 2013-08-08
EP2027156B9 (en) 2011-03-30
NZ573818A (en) 2011-09-30
JP2013090632A (ja) 2013-05-16
CY1111714T1 (el) 2015-10-07
PL2027156T3 (pl) 2011-06-30
AU2007254942B2 (en) 2011-10-27
US7943344B2 (en) 2011-05-17
US20140178935A1 (en) 2014-06-26
KR20090027226A (ko) 2009-03-16
JP5735476B2 (ja) 2015-06-17
EP2027156A2 (en) 2009-02-25
EP2361934A3 (en) 2011-11-02
CA2654025A1 (en) 2007-12-13
NO20085421L (no) 2009-02-27
EP2027156B1 (en) 2011-01-12
MX2008014829A (es) 2009-01-29
AU2007254942A8 (en) 2009-02-05
WO2007143090A3 (en) 2008-03-13
KR101196060B1 (ko) 2012-11-01
JP4686634B2 (ja) 2011-05-25
US8273355B2 (en) 2012-09-25
US20110229462A1 (en) 2011-09-22
EP2361934A2 (en) 2011-08-31
US9096664B2 (en) 2015-08-04
WO2007143090A2 (en) 2007-12-13
SG158112A1 (en) 2010-01-29

Similar Documents

Publication Publication Date Title
IL195037A (en) Linker proteins that link to hepatocyte growth, methods for their production and use
IL219655A0 (en) Hepatocyte growth factor binding proteins and methods of producing the same
EP2069401A4 (en) MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE
ZA201308087B (en) Human antibodies that bind human il-12 and methods for producing
IL210283A0 (en) Prostaglandin e2 binding proteins and uses thereof
IL184995A0 (en) Antibodies that bind transforming growth factor ?? and methods for the production thereof
IL190472A (en) Glyphican Antibody 3 Methods for their preparation and use
IL245666A0 (en) Interleukin-13 binding proteins
GB201015040D0 (en) Novel antigen binding dimer complexes, methods of making and uses thereof
ZA200710264B (en) Anti-IL-6 antibodies, compositions, methods and uses
EP2019842A4 (en) BINDING IMMUNODEPRESSANT ANTIBODIES AND METHODS OF OBTAINING AND USING THESE ANTIBODIES
EP2193145A4 (en) COMPOSITIONS AND METHODS COMPRISING BINDING PROTEINS FOR ADALIMUMAB
IL178761A0 (en) Antibodies and molecules derived therefrom that bind to steap-1 proteins
IL198597A0 (en) Compounds and methods for inhibitiong the interaction of bcl proteins with binding partners
IL186385A0 (en) Antibodies and molecules derived therefrom that bind to 161p2f10b proteins
IL193320A0 (en) Bivalent erbb ligand binding molecules and methods for their preparation and use
GB0718843D0 (en) Materials and methods relating to modifying the binding of antibodies
ZA200809483B (en) Hepatocyte growth factor (HGF) binding proteins
HK1134039A (en) Human antibodies that bind human il-12 and methods for producing
HK1133894A (en) Multispecific epitope binding proteins and uses thereof
HK1156870A (en) Prostaglandin e2 binding proteins and uses thereof
ZA200609068B (en) Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
HK1112410A (en) Antibodies that bind ov064 and methods of use therefor

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed